Hematologic Malignancy
Diffuse Large B-Cell Lymphoma
CI-CAN-00005107DLBCLExplore in graph →
Hematologic355 active trials5 approved drugs19 evidence items
- NCIt
- C8851
- DOID
- 0050745
- Other
- 4 more codes
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005107DLBCLExplore in graph →
Clinical trials
1,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01679119 | Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy(INCA) | completed | Phase 2 | 129 | University College, LondonOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT04300998 | Study of CAR-T Therapy in Older Patients | recruiting | — | 154 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07511114 | A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping | not yet recruiting | Phase 3 | 156 | Ruijin HospitalOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06208735 | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies | recruiting | Phase 1 | 24 | British Columbia Cancer AgencyOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05257018 | R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse | recruiting | Phase 2 | 83 | Fudan UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05618366 | Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma | terminated | Phase 1 | 3 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04824092 | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients(frontMIND) | active not recruiting | Phase 3 | 899 | Incyte CorporationINDUSTRY | 29 | Apr 1, 2026 | clinicaltrials |
| NCT07059650 | DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) | recruiting | Phase 1 / Phase 2 | 150 | Dizal PharmaceuticalsINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT02051257 | Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 51 | City of Hope Medical CenterOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04088890 | Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies | completed | Phase 1 | 52 | Matthew FrankOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07499271 | Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation | recruiting | Phase 2 | 35 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07502118 | NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)(NexCAR19) | recruiting | Phase 2 / Phase 3 | 40 | Health Institutes of TurkeyOTHER_GOV | 1 | Mar 30, 2026 | clinicaltrials |
| NCT01846390 | Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma | completed | Phase 1 | 21 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07498920 | Gut Microbiome in DLBCL Treated With Glofitamab | not yet recruiting | — | 30 | Peking Union Medical College HospitalOTHER | 0 | Mar 27, 2026 | clinicaltrials |
| NCT05068440 | Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib | completed | Phase 2 | 65 | BeiGeneINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07493109 | Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP | recruiting | Phase 3 | 200 | Ou Bai, MD/PHDOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07493148 | Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL | recruiting | Phase 2 | 50 | Ou Bai, MD/PHDOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07493486 | IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study | completed | Phase 2 | 31 | Zhejiang Cancer HospitalOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04661943 | Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma | completed | Phase 2 | 30 | Ou Bai, MD/PHDOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT05514327 | A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL | recruiting | N/A | 20 | Peking Union Medical College HospitalOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT04830137 | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | recruiting | Phase 1 | 248 | Nurix Therapeutics, Inc.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT02952508 | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom(CLOVER-WaM) | active not recruiting | Phase 2 | 120 | Cellectar Biosciences, Inc.INDUSTRY | 11 | Mar 18, 2026 | clinicaltrials |
| NCT07480850 | Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03547115 | A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML | terminated | Phase 1 | 84 | MEI Pharma, Inc.INDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06026319 | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma | recruiting | Phase 1 | 24 | Marcela V. Maus, M.D.,Ph.D.OTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07473167 | Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients(TC011) | recruiting | Phase 1 / Phase 2 | 98 | TICAROS Co., Ltd.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT04676360 | Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma | terminated | Phase 2 | 10 | Jacob Soumerai, MDOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07463781 | Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy(NEURO_CAR-T) | not yet recruiting | — | 100 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT02213913 | Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas | completed | Phase 1 / Phase 2 | 55 | University of ChicagoOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT05256641 | Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT02446457 | Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 2 | 53 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05934448 | Pembro Plus CAR T-cell Therapy in R/R in PMBCL | recruiting | Phase 2 | 35 | Jennifer Crombie, MDOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07042438 | Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells | recruiting | Phase 2 | 56 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05546268 | Study of Oral MRT-2359 in Selected Cancer Patients | active not recruiting | Phase 1 / Phase 2 | 174 | Monte Rosa Therapeutics, IncINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04319237 | Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes | completed | — | 60 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07215832 | Karyopharm Expanded Access Program for Selinexor(KEAP) | available | — | — | Karyopharm Therapeutics IncINDUSTRY | 0 | Mar 2, 2026 | clinicaltrials |
| NCT07443514 | Cognitive Impairment in Patients With Diffuse Large B-Cell Lymphoma | recruiting | N/A | 3 | Institute of Oncology LjubljanaOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04205838 | Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma | terminated | Phase 2 | 23 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05755087 | Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma | recruiting | Phase 1 | 18 | Lapo AlinariOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04186520 | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies | recruiting | Phase 1 / Phase 2 | 100 | Medical College of WisconsinOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05432635 | Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT03990961 | Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) | terminated | Phase 2 | 5 | University of ChicagoOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04282018 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | completed | Phase 1 / Phase 2 | 97 | BeiGeneINDUSTRY | 2 | Feb 20, 2026 | clinicaltrials |
| NCT04512716 | Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma | recruiting | Early Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06830759 | Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma(EpcoReal) | recruiting | — | 700 | AbbVieINDUSTRY | 13 | Feb 17, 2026 | clinicaltrials |
| NCT04775745 | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. | recruiting | Phase 1 | 60 | Newave Pharmaceutical IncINDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05544019 | Study of SGR-1505 in Mature B-Cell Neoplasms | recruiting | Phase 1 | 98 | Schrödinger, Inc.INDUSTRY | 8 | Feb 13, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 7, 2026source: clinicaltrials